REGENERON PHARMACEUTICALS, INC. Long-term Line of Credit
REGENERON PHARMACEUTICALS, INC. (REGN) had Long-term Line of Credit of $0 as of 2018-12-31, per its 10-K filed 2019-02-07.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2019-02-07
- 2018-12-31: Long-term Line of Credit $0.00.
| Period end | Long-term Line of Credit |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |